Soleus Capital Management, L.P. Buys DICE Therapeutics Inc, United Therapeutics Corp, Flexion Therapeutics Inc, Sells NovoCure, The Beauty Health Co, IVERIC bio Inc

• New Purchases: DICE, UTHR, FLXN, ENTA, ORGO, NRIX, CTSO, ANGO, GLPG, SLGC, VNDA, TVTX, AVIR, PIRS, PCRX, DALS, ARNA, VIVO, CORT, CDMO, ZGNX, BVS, CTMX, NGM, PRCT,
• Added Positions: LNTH, CDNA, SRDX, SIEN, EPIX, NPCE, NTRA, AZN, YMAB, CVRX, KRYS, EDAP, INSP, THTX, FDMT, EOLS, LYRA, LUNG,
• Reduced Positions: NVCR, SKIN, BCAB, ISEE, ITMR, NEO, CCCC, CUTR, EDIT, INBX, CELC, BEAM, CRSP, IRMD, GLUE, RFL, PCVX, XENE, ATXS,
• Sold Out: MDXG, RVMD, TKNO, GLTO, DXCM, PODD, ESTA, MSON, GH, HALO, CMAX, RNLX, SBTX, MGTA, TCRR, NARI, KDMN, RPTX,

For the details of Soleus Capital Management, L.P.'s stock buys and sells, go to https://www.gurufocus.com/guru/soleus+capital+management%2C+l.p./current-portfolio/portfolio

1. BioAtla Inc (BCAB) - 2,515,424 shares, 11.74% of the total portfolio. Shares reduced by 9.98%
2. C4 Therapeutics Inc (CCCC) - 750,633 shares, 5.32% of the total portfolio. Shares reduced by 13.8%
3. Lantheus Holdings Inc (LNTH) - 1,229,827 shares, 5.01% of the total portfolio. Shares added by 34.60%
4. DICE Therapeutics Inc (DICE) - 879,903 shares, 4.57% of the total portfolio. New Position
5. Theratechnologies Inc (THTX) - 7,612,383 shares, 4.53% of the total portfolio. Shares added by 8.31%

Soleus Capital Management, L.P. initiated holding in DICE Therapeutics Inc. The purchase prices were between $31.92 and $37, with an estimated average price of $34.06. The stock is now traded at around $31.710000. The impact to a portfolio due to this purchase was 4.57%. The holding were 879,903 shares as of 2021-09-30.

Soleus Capital Management, L.P. initiated holding in United Therapeutics Corp. The purchase prices were between $179.86 and $214.88, with an estimated average price of $196.99. The stock is now traded at around $205.030000. The impact to a portfolio due to this purchase was 2.98%. The holding were 101,800 shares as of 2021-09-30.

Soleus Capital Management, L.P. initiated holding in Flexion Therapeutics Inc. The purchase prices were between $4.4 and $8.2, with an estimated average price of $6.26. The stock is now traded at around $9.160000. The impact to a portfolio due to this purchase was 2.02%. The holding were 2,084,050 shares as of 2021-09-30.

Soleus Capital Management, L.P. initiated holding in Enanta Pharmaceuticals Inc. The purchase prices were between $41.02 and $58.65, with an estimated average price of $49.48. The stock is now traded at around $89.880000. The impact to a portfolio due to this purchase was 1.64%. The holding were 182,400 shares as of 2021-09-30.

Soleus Capital Management, L.P. initiated holding in Organogenesis Holdings Inc. The purchase prices were between $13.71 and $17.18, with an estimated average price of $15.57. The stock is now traded at around $10.800000. The impact to a portfolio due to this purchase was 1.45%. The holding were 639,887 shares as of 2021-09-30.

Soleus Capital Management, L.P. initiated holding in Nurix Therapeutics Inc. The purchase prices were between $22.71 and $36.69, with an estimated average price of $30.82. The stock is now traded at around $33.920000. The impact to a portfolio due to this purchase was 1.25%. The holding were 263,900 shares as of 2021-09-30.

Soleus Capital Management, L.P. added to a holding in Lantheus Holdings Inc by 34.60%. The purchase prices were between $24.23 and $28.59, with an estimated average price of $26.18. The stock is now traded at around $29.790000. The impact to a portfolio due to this purchase was 1.29%. The holding were 1,229,827 shares as of 2021-09-30.

Soleus Capital Management, L.P. added to a holding in CareDx Inc by 332.29%. The purchase prices were between $59.15 and $91.99, with an estimated average price of $76.35. The stock is now traded at around $46.990000. The impact to a portfolio due to this purchase was 0.98%. The holding were 126,661 shares as of 2021-09-30.

Soleus Capital Management, L.P. added to a holding in Surmodics Inc by 37.04%. The purchase prices were between $52.8 and $60.32, with an estimated average price of $55.61. The stock is now traded at around $48.880000. The impact to a portfolio due to this purchase was 0.91%. The holding were 381,522 shares as of 2021-09-30.

Soleus Capital Management, L.P. added to a holding in Sientra Inc by 63.25%. The purchase prices were between $5.33 and $8.53, with an estimated average price of $6.84. The stock is now traded at around $5.180000. The impact to a portfolio due to this purchase was 0.84%. The holding were 2,386,063 shares as of 2021-09-30.

Soleus Capital Management, L.P. added to a holding in ESSA Pharma Inc by 28.15%. The purchase prices were between $7.76 and $29.37, with an estimated average price of $15.99. The stock is now traded at around $12.990000. The impact to a portfolio due to this purchase was 0.8%. The holding were 2,868,023 shares as of 2021-09-30.

Soleus Capital Management, L.P. added to a holding in NeuroPace Inc by 20.64%. The purchase prices were between $15.85 and $25.07, with an estimated average price of $21.07. The stock is now traded at around $12.830000. The impact to a portfolio due to this purchase was 0.72%. The holding were 1,670,136 shares as of 2021-09-30.

Soleus Capital Management, L.P. sold out a holding in MiMedx Group Inc. The sale prices were between $5.52 and $15.83, with an estimated average price of $11.35.

Soleus Capital Management, L.P. sold out a holding in Revolution Medicines Inc. The sale prices were between $23.95 and $33.41, with an estimated average price of $29.16.

Soleus Capital Management, L.P. sold out a holding in Alpha Teknova Inc. The sale prices were between $17.47 and $27.49, with an estimated average price of $21.39.

Soleus Capital Management, L.P. sold out a holding in Galecto Inc. The sale prices were between $3.59 and $5, with an estimated average price of $4.29.

Soleus Capital Management, L.P. sold out a holding in Insulet Corp. The sale prices were between $260.36 and $307.27, with an estimated average price of $285.43.

Soleus Capital Management, L.P. sold out a holding in DexCom Inc. The sale prices were between $426.84 and $572.73, with an estimated average price of $503.9.